TY - JOUR
T1 - The role of therapy in impairing quality of life in dermatological patients
T2 - A multinational study
AU - Balieva, Flora N.
AU - Finlay, Andrew Y.
AU - Kupfer, Jörg
AU - Tomas Aragones, Lucia
AU - Lien, Lars
AU - Gieler, Uwe
AU - Poot, Francoise
AU - Jemec, Gregor B.E.
AU - Misery, Laurent
AU - Kemeny, Lajos
AU - Sampogna, Francesca
AU - Van Middendorp, Henriët
AU - Halvorsen, Jon Anders
AU - Ternowitz, Thomas
AU - Szepietowski, Jacek C.
AU - Potekaev, Nikolay
AU - Marron, Servando E.
AU - Altunay, Ilknur K.
AU - Salek, Sam S.
AU - Dalgard, Florence J.
PY - 2018/6
Y1 - 2018/6
N2 - Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/ drug reactions (10.2%), psoriasis (9.9%), vasculi-tis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
AB - Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/ drug reactions (10.2%), psoriasis (9.9%), vasculi-tis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.
KW - Burden of skin disease
KW - Dermatological therapy
KW - DLQI
KW - HRQoL
KW - Quality of life
KW - Therapy burden
UR - http://www.scopus.com/inward/record.url?scp=85048506517&partnerID=8YFLogxK
U2 - 10.2340/00015555-2918
DO - 10.2340/00015555-2918
M3 - Article
C2 - 29507999
AN - SCOPUS:85048506517
VL - 98
SP - 563
EP - 569
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
SN - 0001-5555
IS - 6
ER -